 | • レポートコード：MRC2305A029 • 出版社/出版日：Transparency Market Research / 2023年3月2日 • レポート形態：英文、PDF、158ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当調査レポートによると、世界の心臓幹細胞市場規模が、2023年の26億ドルから2031年に51億ドルとなり、予測期間中に年平均7.4%で成長すると推測されています。本レポートは、心臓幹細胞の世界市場について徹底的に分析・調査を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、細胞種類別（胚性幹細胞、成体幹細胞、人工多能性幹細胞、臍帯血幹細胞・羊水幹細胞）分析、用途別（心不全、心筋梗塞、重症虚血肢、その他）分析、ソース別（自家、同種）分析、エンドユーザー別（製薬・バイオテクノロジー企業、病院・細胞バンク、学術・研究機関）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況など、以下の項目を整理しています。また、Astellas Pharma, Inc.、STEMCELL Technologies、Cellular Engineering Technologies、BioTimes, Inc.、Takara Bio, Inc.、U.S. Stem Cell, Inc.、BrainStorm Cell Limited.、Cytori Therapeutics, Inc.、Lisata Therapeutics、Bio Cardia, Inc.など、主要企業情報を含んでいます。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の心臓幹細胞市場規模：細胞種類別 - 胚性幹細胞における市場規模 - 成体幹細胞における市場規模 - 人工多能性幹細胞における市場規模 - 臍帯血幹細胞・羊水幹細胞における市場規模 ・世界の心臓幹細胞市場規模：用途別 - 心不全における市場規模 - 心筋梗塞における市場規模 - 重症虚血肢における市場規模 - その他用途における市場規模 ・世界の心臓幹細胞市場規模：ソース別 - 自家細胞の市場規模 - 同種細胞の市場規模 ・世界の心臓幹細胞市場規模：エンドユーザー別 - 製薬・バイオテクノロジー企業における市場規模 - 病院・細胞バンクにおける市場規模 - 学術・研究機関における市場規模 ・世界の心臓幹細胞市場規模：地域別 - 北米の心臓幹細胞市場規模 - ヨーロッパの心臓幹細胞市場規模 - アジア太平洋の心臓幹細胞市場規模 - 中南米の心臓幹細胞市場規模 - 中東・アフリカの心臓幹細胞市場規模 ・競争状況 |
Cardiology Stem Cells Market – Scope of Report
TMR’s report on the global cardiology stem cells market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global cardiology stem cells market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cardiology stem cells market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the cardiology stem cells market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global cardiology stem cells market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global cardiology stem cells market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global cardiology stem cells market.
The report delves into the competitive landscape of the global cardiology stem cells market. Key players operating in the global cardiology stem cells market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global cardiology stem cells market profiled in this report.
Key Questions Answered in Global Cardiology Stem Cells Market Report
• What is the sales/revenue generated by cardiology stem cells across all regions during the forecast period?
• What are the opportunities in the global cardiology stem cells market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Cardiology Stem Cells Market – Research Objectives and Research Approach
The comprehensive report on the global cardiology stem cells market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global cardiology stem cells market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global cardiology stem cells market.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiology Stem Cells Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiology Stem Cells Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Bn)
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.3. Pipeline Analysis
5.4. Disease Prevalence & Incidence Rate globally with key countries
6. Global Cardiology Stem Cells Market Analysis and Forecast, by Type of Cell
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type of Cell, 2017-2031
6.3.1. Embryonic Stem Cells
6.3.2. Adult Stem Cells
6.3.3. Induced Pluripotent Stem Cells
6.3.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
6.4. Market Attractiveness Analysis, by Type of Cell
7. Global Cardiology Stem Cells Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017-2031
7.3.1. Heart Failure
7.3.2. Myocardial Infarction
7.3.3. Critical Limb Ischemia
7.3.4. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Cardiology Stem Cells Market Analysis and Forecast, by Source
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Source, 2017-2031
8.3.1. Autologous
8.3.2. Allogenic
8.4. Market Attractiveness Analysis, by Source
9. Global Cardiology Stem Cells Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Pharmaceutical & Biotechnology Companies
9.3.2. Hospitals & Cell Banks
9.3.3. Academic & Research Institutes
9.4. Market Attractiveness Analysis, by End-user
10. Global Cardiology Stem Cells Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Cardiology Stem Cells Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type of Cell, 2017-2031
11.2.1. Embryonic Stem Cells
11.2.2. Adult Stem Cells
11.2.3. Induced Pluripotent Stem Cells
11.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
11.3. Market Value Forecast, by Application, 2017-2031
11.3.1. Heart Failure
11.3.2. Myocardial Infarction
11.3.3. Critical Limb Ischemia
11.3.4. Others
11.4. Market Value Forecast, by Source, 2017-2031
11.4.1. Autologous
11.4.2. Allogenic
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Pharmaceutical & Biotechnology Companies
11.5.2. Hospitals & Cell Banks
11.5.3. Academic & Research Institutes
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type of Cell
11.7.2. By Application
11.7.3. By Source
11.7.4. By End-user
11.7.5. By Country
12. Europe Cardiology Stem Cells Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type of Cell, 2017-2031
12.2.1. Embryonic Stem Cells
12.2.2. Adult Stem Cells
12.2.3. Induced Pluripotent Stem Cells
12.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
12.3. Market Value Forecast, by Application, 2017-2031
12.3.1. Heart Failure
12.3.2. Myocardial Infarction
12.3.3. Critical Limb Ischemia
12.3.4. Others
12.4. Market Value Forecast, by Source, 2017-2031
12.4.1. Autologous
12.4.2. Allogenic
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Pharmaceutical & Biotechnology Companies
12.5.2. Hospitals & Cell Banks
12.5.3. Academic & Research Institutes
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type of Cell
12.7.2. By Application
12.7.3. By Source
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Cardiology Stem Cells Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type of Cell, 2017-2031
13.2.1. Embryonic Stem Cells
13.2.2. Adult Stem Cells
13.2.3. Induced Pluripotent Stem Cells
13.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
13.3. Market Value Forecast, by Application, 2017-2031
13.3.1. Heart Failure
13.3.2. Myocardial Infarction
13.3.3. Critical Limb Ischemia
13.3.4. Others
13.4. Market Value Forecast, by Source, 2017-2031
13.4.1. Autologous
13.4.2. Allogenic
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Pharmaceutical & Biotechnology Companies
13.5.2. Hospitals & Cell Banks
13.5.3. Academic & Research Institutes
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type of Cell
13.7.2. By Application
13.7.3. By Source
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Cardiology Stem Cells Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type of Cell, 2017-2031
14.2.1. Embryonic Stem Cells
14.2.2. Adult Stem Cells
14.2.3. Induced Pluripotent Stem Cells
14.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
14.3. Market Value Forecast, by Application, 2017-2031
14.3.1. Heart Failure
14.3.2. Myocardial Infarction
14.3.3. Critical Limb Ischemia
14.3.4. Others
14.4. Market Value Forecast, by Source, 2017-2031
14.4.1. Autologous
14.4.2. Allogenic
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Pharmaceutical & Biotechnology Companies
14.5.2. Hospitals & Cell Banks
14.5.3. Academic & Research Institutes
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type of Cell
14.7.2. By Application
14.7.3. By Source
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Cardiology Stem Cells Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type of Cell, 2017-2031
15.2.1. Embryonic Stem Cells
15.2.2. Adult Stem Cells
15.2.3. Induced Pluripotent Stem Cells
15.2.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
15.3. Market Value Forecast, by Application, 2017-2031
15.3.1. Heart Failure
15.3.2. Myocardial Infarction
15.3.3. Critical Limb Ischemia
15.3.4. Others
15.4. Market Value Forecast, by Source, 2017-2031
15.4.1. Autologous
15.4.2. Allogenic
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Pharmaceutical & Biotechnology Companies
15.5.2. Hospitals & Cell Banks
15.5.3. Academic & Research Institutes
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type of Cell
15.7.2. By Application
15.7.3. By Source
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2022)
16.3. Company Profiles
16.3.1. Astellas Pharma, Inc.
16.3.1.1. Company Overview
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Strategic Overview
16.3.2. STEMCELL Technologies
16.3.2.1. Company Overview
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Strategic Overview
16.3.3. Cellular Engineering Technologies
16.3.3.1. Company Overview
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Strategic Overview
16.3.4. BioTimes, Inc.
16.3.4.1. Company Overview
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Strategic Overview
16.3.5. Takara Bio, Inc.
16.3.5.1. Company Overview
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Strategic Overview
16.3.6. U.S. Stem Cell, Inc.
16.3.6.1. Company Overview
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Strategic Overview
16.3.7. BrainStorm Cell Limited
16.3.7.1. Company Overview
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Strategic Overview
16.3.8. Cytori Therapeutics, Inc.
16.3.8.1. Company Overview
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Strategic Overview
16.3.9. Bio Cardia, Inc.
16.3.9.1. Company Overview
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Strategic Overview